JP2023524414A5 - - Google Patents

Info

Publication number
JP2023524414A5
JP2023524414A5 JP2022565544A JP2022565544A JP2023524414A5 JP 2023524414 A5 JP2023524414 A5 JP 2023524414A5 JP 2022565544 A JP2022565544 A JP 2022565544A JP 2022565544 A JP2022565544 A JP 2022565544A JP 2023524414 A5 JP2023524414 A5 JP 2023524414A5
Authority
JP
Japan
Prior art keywords
dnaj
fusion protein
group
aav
tdp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022565544A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023524414A (ja
JP7894321B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/029289 external-priority patent/WO2021222168A2/en
Publication of JP2023524414A publication Critical patent/JP2023524414A/ja
Publication of JP2023524414A5 publication Critical patent/JP2023524414A5/ja
Priority to JP2026067788A priority Critical patent/JP2026123053A/ja
Application granted granted Critical
Publication of JP7894321B2 publication Critical patent/JP7894321B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022565544A 2020-04-28 2021-04-27 Tdp-43プロテイノパチーの処置のための組成物および方法 Active JP7894321B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026067788A JP2026123053A (ja) 2020-04-28 2026-04-16 Tdp-43プロテイノパチーの処置のための組成物および方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063016707P 2020-04-28 2020-04-28
US63/016,707 2020-04-28
US202063035437P 2020-06-05 2020-06-05
US63/035,437 2020-06-05
PCT/US2021/029289 WO2021222168A2 (en) 2020-04-28 2021-04-27 Compositions and methods for the treatment of tdp-43 proteinopathies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026067788A Division JP2026123053A (ja) 2020-04-28 2026-04-16 Tdp-43プロテイノパチーの処置のための組成物および方法

Publications (3)

Publication Number Publication Date
JP2023524414A JP2023524414A (ja) 2023-06-12
JP2023524414A5 true JP2023524414A5 (cg-RX-API-DMAC7.html) 2024-05-09
JP7894321B2 JP7894321B2 (ja) 2026-07-23

Family

ID=75905076

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022565544A Active JP7894321B2 (ja) 2020-04-28 2021-04-27 Tdp-43プロテイノパチーの処置のための組成物および方法
JP2026067788A Pending JP2026123053A (ja) 2020-04-28 2026-04-16 Tdp-43プロテイノパチーの処置のための組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026067788A Pending JP2026123053A (ja) 2020-04-28 2026-04-16 Tdp-43プロテイノパチーの処置のための組成物および方法

Country Status (10)

Country Link
US (1) US20240327477A1 (cg-RX-API-DMAC7.html)
EP (1) EP4143215A2 (cg-RX-API-DMAC7.html)
JP (2) JP7894321B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230025659A (cg-RX-API-DMAC7.html)
CN (2) CN115836129B (cg-RX-API-DMAC7.html)
AU (1) AU2021265088A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022021604A2 (cg-RX-API-DMAC7.html)
MX (1) MX2022013288A (cg-RX-API-DMAC7.html)
TW (1) TW202206446A (cg-RX-API-DMAC7.html)
WO (1) WO2021222168A2 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021367952A1 (en) * 2020-10-26 2023-06-08 Sola Biosciences Llc Compositions and methods for the treatment of alzheimer's disease
US20250205305A1 (en) * 2022-01-27 2025-06-26 The Trustees Of Columbia University In The City Of New York Systems, methods, and compositions for rescuing protein misfolding
WO2023185017A1 (zh) * 2022-03-30 2023-10-05 呈诺再生医学科技(珠海横琴新区)有限公司 经修饰的rnf112或包含其的外泌体递送系统
CN114874332B (zh) * 2022-03-30 2023-01-10 呈诺再生医学科技(珠海横琴新区)有限公司 经修饰的rnf112作为治疗als药物的应用
CN122070299A (zh) * 2023-09-15 2026-05-19 普罗塞纳生物科学有限公司 细胞穿透剂及其用途
WO2025264861A1 (en) * 2024-06-18 2025-12-26 Yale University Compositions of bi-functional alpha helical peptides and methods thereof for treating tdp-43 proteinopathies

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8918616D0 (en) 1989-08-15 1989-09-27 Univ Glasgow Herpes simplex virus type 1 mutant
US5804413A (en) 1992-07-31 1998-09-08 University Of Pittsburgh Of The Commonwealth System Of Higher Education Herpes simplex virus strains for gene transfer
GB9415319D0 (en) 1994-07-29 1994-09-21 Medical Res Council HSV viral vector
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US6093570A (en) 1995-06-07 2000-07-25 The University Of North Carolina At Chapel Hill Helper virus-free AAV production
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
EP1002119A1 (en) 1997-07-31 2000-05-24 University Of Pittsburgh Of The Commonwealth System Of Higher Education Targeted hsv vectors
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
DE69939169D1 (de) 1998-05-28 2008-09-04 Us Gov Health & Human Serv Aav5 vektoren und deren verwendung
US7465583B2 (en) 2000-06-01 2008-12-16 The University Of North Carolina At Chapel Hill Duplexed parvovirus vectors
WO2002053703A2 (en) 2001-01-05 2002-07-11 Children's Hospital, Inc. Aav2 vectors and methods
CN103589692B (zh) 2001-11-13 2018-07-24 宾夕法尼亚大学托管会 检测和/或鉴定腺伴随病毒(aav)序列以及分离所鉴定的新型序列的方法
DK2359869T3 (en) 2001-12-17 2019-04-15 Univ Pennsylvania Sequences of adeno-associated virus (AAV) serotype 8, vectors containing these, and uses thereof
EP1668143B1 (en) 2003-09-30 2013-03-20 The Trustees of The University of Pennsylvania Adeno-associated virus (aav) clades, sequences, vectors containing same, and uses therefor
EP1828390B1 (en) 2004-12-15 2012-06-13 The University Of North Carolina At Chapel Hill Chimeric vectors
EP2396343B1 (en) 2009-02-11 2017-05-17 The University of North Carolina At Chapel Hill Modified virus vectors and methods of making and using the same
WO2010111587A1 (en) * 2009-03-26 2010-09-30 Trustees Of The University Of Pennsylvania Modulators of tdp-43 mediated toxicity
US9169494B2 (en) 2010-01-12 2015-10-27 The University Of North Carolina At Chapel Hill Restrictive inverted terminal repeats for viral vectors
WO2011097456A2 (en) 2010-02-05 2011-08-11 The University Of North Carolina At Chapel Hill Compositions and methods for enhanced parvovirus transduction
CA2853412C (en) 2011-10-28 2021-05-04 University Of Zurich Tdp-43 specific binding molecules
WO2014038884A1 (ko) * 2012-09-07 2014-03-13 주식회사 마크로젠 융합 단백질 및 이를 포함하는 암 진단용 조성물
WO2014053879A1 (en) 2012-10-04 2014-04-10 Centre National De La Recherche Scientifique Cell penetrating peptides for intracellular delivery of molecules
EP2929045B1 (en) * 2012-12-05 2020-12-02 SOLA Biosciences LLC Protein expression enhancing polypeptides
US20160220649A1 (en) * 2013-09-13 2016-08-04 Fundación Pública Andaluza Progreso Y Salud Combinations of aggregating proteins and molecular chaperone proteins for the treatment of proteinopathies or conformational diseases
WO2016053610A1 (en) 2014-10-03 2016-04-07 Academia Sinica Antibodies against pathological forms of tdp-43 and uses thereof
CA2874083C (en) * 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
US10720797B2 (en) 2017-05-26 2020-07-21 California Institute Of Technology Method and apparatus for dynamic RF lens focusing and tracking of wireless power recovery unit
US11466077B2 (en) 2018-01-05 2022-10-11 Ac Immune Sa Misfolded TDP-43 binding molecules
JP7320282B2 (ja) 2018-03-16 2023-08-03 国立大学法人滋賀医科大学 異常tdp-43を分解除去する抗体断片

Similar Documents

Publication Publication Date Title
Lu Recombinant adeno-associated virus as delivery vector for gene therapy—a review
US20220331409A1 (en) Factor ix gene therapy
JP6619454B2 (ja) キャプシド
JP2020522269A5 (cg-RX-API-DMAC7.html)
EP3221456B1 (en) Genome-modified recombinant adeno-associated virus vectors
JP5704361B2 (ja) 神経系細胞への遺伝子導入のためのアデノ随伴ウイルスビリオン
JP2021106619A5 (cg-RX-API-DMAC7.html)
JP2021512649A5 (cg-RX-API-DMAC7.html)
JP2023529371A5 (cg-RX-API-DMAC7.html)
JP2018522529A5 (cg-RX-API-DMAC7.html)
RU2018116076A (ru) Модифицированные гены атаксии фридрейха и векторы для генной терапии
JP2022531809A5 (cg-RX-API-DMAC7.html)
JP2025069281A (ja) 調節可能な発現系
EP1313869A2 (en) Helper functions for recombinant vector production
JP2022525302A5 (cg-RX-API-DMAC7.html)
JP2017529395A5 (cg-RX-API-DMAC7.html)
JP2023520927A5 (cg-RX-API-DMAC7.html)
JP2023553005A5 (cg-RX-API-DMAC7.html)
JP2023537358A5 (cg-RX-API-DMAC7.html)
JP2020519294A5 (cg-RX-API-DMAC7.html)
CN112011571A (zh) 一种用于治疗脊髓性肌萎缩的基因治疗药物
US11780886B2 (en) Modified viral vectors and methods of making and using the same
JP2022542829A5 (cg-RX-API-DMAC7.html)
Lee et al. Efficient gene expression by self-complementary adeno-associated virus serotype 2 and 5 in various human cancer cells
JP2023548632A5 (cg-RX-API-DMAC7.html)